XERS — Xeris Biopharma Holdings Share Price
Last trade - 00:00- $268.27m
- $386.75m
- $163.91m
- 45
- 48
- 80
- 59
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.6% | ||
| Return on Equity | -324.2% | ||
| Operating Margin | -28.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.72 | 20.43 | 49.59 | 110.25 | 163.91 | 184.43 | 219.34 | 131.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.
Directors
- Paul Edick CHM (65)
- John Shannon PRE (59)
- Steven Prestrelski CFD (57)
- Steven Pieper CFO (44)
- Beth Hecht SVP (57)
- Kenneth Johnson SVP (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 20th, 2021
- Public Since
- June 21st, 2018
- No. of Shareholders
- 225
- No. of Employees
- 377
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 140,453,467
- Address
- 1375 West Fulton Street, Suite 1300, CHICAGO, 60607
- Web
- https://www.xerispharma.com/
- Phone
- +1 3026587581
- Contact
- Allison Wey
- Auditors
- KPMG LLP
Latest News for XERS
Upcoming Events for XERS
Similar to XERS
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
As of Today at 19:24 UTC, shares in Xeris Biopharma Holdings are trading at $1.91. This share price information is delayed by 15 minutes.
Shares in Xeris Biopharma Holdings last closed at $1.91 and the price had moved by -12.39% over the past 365 days. In terms of relative price strength the Xeris Biopharma Holdings share price has underperformed the S&P500 Index by -29.24% over the past year.
The overall consensus recommendation for Xeris Biopharma Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Xeris Biopharma Holdings does not currently pay a dividend.
Xeris Biopharma Holdings does not currently pay a dividend.
Xeris Biopharma Holdings does not currently pay a dividend.
To buy shares in Xeris Biopharma Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.91, shares in Xeris Biopharma Holdings had a market capitalisation of $268.27m.
Here are the trading details for Xeris Biopharma Holdings:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: XERS
Based on an overall assessment of its quality, value and momentum Xeris Biopharma Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Xeris Biopharma Holdings is $4.75. That is 148.69% above the last closing price of $1.91.
Analysts covering Xeris Biopharma Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$0.39 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xeris Biopharma Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +3.2%.
As of the last closing price of $1.91, shares in Xeris Biopharma Holdings were trading -14.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Xeris Biopharma Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Xeris Biopharma Holdings' management team is headed by:
- Paul Edick - CHM
- John Shannon - PRE
- Steven Prestrelski - CFD
- Steven Pieper - CFO
- Beth Hecht - SVP
- Kenneth Johnson - SVP